...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Fusion protein Ag85B-MPT64 sub(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice
【24h】

Fusion protein Ag85B-MPT64 sub(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice

机译：融合蛋白Ag85B-MPT64 sub（190-198）-Mtb8.4具有比Ag85B更高的免疫原性，并具有增强BCG引发的小鼠抗结核分枝杆菌免疫力的能力

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tuberculosis (TB) remains a major infectious disease worldwide despite chemotherapy and BCG vaccine. The efficacy of the current TB vaccine BCG varies from 0 to 80%. New vaccines that have better protection than BCG or have the capability to boost BCG-primed immunity are urgently needed. We have previously constructed a fusion protein Ag85B-MPT64 sub(190-198)-Mtb8.4 (AMM). In this study, we investigated the immunogenicity of the fusion protein AMM in a novel adjuvant of dimethyl-dioctyldecyl ammonium bromide and BCG polysaccharide nucleic acid (DDA-BCG PSN), and its capacity to boost BCG-primed immunity. The anti-Ag85B antibodies IgG1 and IgG2a were determined using ELISA and the number of spleen cells secreting IFN- gamma was determined by ELISPOT. In addition, the ability of the subunit vaccine AMM to boost BCG-primed immunity against Mycobacterium tuberculosis was analyzed. The fusion protein AMM induced more effective humoral and cell-mediated immune responses in mice than Ag85B alone. Mice primed with BCG vaccination followed by boosting with AMM produced a stronger immune response and afforded a better protection against M. tuberculosis infection than mice immunized with BCG alone or BCG priming followed by boosting with Ag85B. These findings suggest that AMM is a promising candidate subunit vaccine to enhance the protective efficiency of BCG.
机译：尽管有化学疗法和BCG疫苗，结核病（TB）仍然是世界范围内的主要传染病。当前的结核病疫苗卡介苗的功效从0到80％不等。迫切需要具有比BCG更好的保护或能够增强BCG初免的能力的新疫苗。我们先前已经构建了融合蛋白Ag85B-MPT64 sub（190-198）-Mtb8.4（AMM）。在这项研究中，我们调查了融合蛋白AMM在二甲基二辛基癸基溴化铵和BCG多糖核酸（DDA-BCG PSN）的新型佐剂中的免疫原性，以及其增强BCG免疫的能力。使用ELISA确定抗Ag85B抗体IgG1和IgG2a，并且通过ELISPOT确定分泌IFN-γ的脾细胞的数目。另外，分析了亚单位疫苗AMM增强BCG引发的针对结核分枝杆菌的免疫的能力。与单独的Ag85B相比，融合蛋白AMM在小鼠中诱导了更有效的体液和细胞介导的免疫反应。与仅用BCG免疫或BCG免疫后再用Ag85B免疫的小鼠相比，用BCG疫苗接种后再用AMM加强免疫的小鼠产生了更强的免疫反应，并提供了更好的针对结核分枝杆菌感染的保护。这些发现表明，AMM是增强BCG保护效率的有前途的候选亚单位疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号